Press Room

Warning message

The subscription service is currently unavailable. Please try again later.

Blog

Immunogenicity study communication
28Nov17

KYMOS communication in the 10th EBF Symposium

Kymos presented an oral communication on the immunogenicity of gonadotrophines used for ovarian stimulation, during the 10th EBF Open Symposium held past 15-17 November 2017 in Barcelona. Kymos' Immunology Manager, Dr. Carles Morte, shared with the attendees the bioanalytical strategy followed and the results of two clinical studies. This work was done in collaboration with IBSA (Switzerland), the University of Basel (Switzerland), the Semmelweis University (Budapest, Hungary) and the Institut Universitari Dexeus (Barcelona, Spain).

 

FDA logo
20Nov17

FDA recognizes 8 European Agencies for inspections

The U.S. Food and Drug Administration has determined the agency will recognize eight European drug regulatory authorities as capable of conducting inspections of manufacturing facilities that meet FDA requirements. The eight regulatory authorities found to be capable are those located in: Austria, Croatia, France, Italy, Malta, Spain, Sweden and the United Kingdom.

Kymos stand at CPhI 2017 in Frankfurt
30Oct17

Kymos in the CPhI 2017 in Frankfurt

KYMOS and its Italian affiliate PHARMAPROGRESS have particIpated in the Worldwide CPhI 2017 in Frankfurt during October 24-26. The stand was very attended and we had around 80 meeting with current and potencial partners. We thank all our visitors for their interest and friendliness.

17Sep17

CRO Market Growth

The global CRO market value is expected to exceed $32 billion in 2017 and reach $45 billion by 2022, according to a report by Grand View Research, with growth attributed to greater R&D spend, M&A activity, as well as government contracts with CROs. The role of CROs in helping pharma and biopharma firms address today’s complex drug development challenges, has grown considerably these past few years.